Eli Lilly Expects 30% Revenue Growth, FDA Approval Plans

Eli Lilly & Co. (LLY) is currently positioned for potential growth, with expectations of strong earnings and significant drug approvals in 2025 and 2026, including the FDA submission of the oral weight loss drug orforglipron and Phase 3 trial results for retatrutide. The company has demonstrated impressive long-term performance, with a 10-year annualized return of 24.53%, significantly outperforming the market and showcasing the power of compounded returns. Jim Cramer has expressed bullish sentiment on Eli Lilly, highlighting its robust drug pipeline, expansion plans in U.S. manufacturing, and potential benefits from tariffs on European competitors, although he notes possible short-term challenges with weight loss drug demand and the need for new breakthroughs. Recently, the stock has experienced some volatility, with a notable trading range between $677.09 and $972.53 over the past year, and mixed analyst ratings that predominantly favor buying or holding the stock. However, some large investors have taken a bearish stance in options trading, signaling uncertainty about the stock’s near-term direction, with significant put volume suggesting expectations of a price range between $500 and $850. Overall, Eli Lilly remains a key player in pharmaceuticals with strong growth prospects but faces both market and product cycle risks that investors should monitor.